Should you buy Eton Pharmaceuticals stock now?
Yes, the technical signal for Eton Pharmaceuticals is currently BUY. Eton Pharmaceuticals trades at $45.00 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 2.955 with rising momentum (signal: 2.952); RSI is at 63.6 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $54.75 points to 21.7% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Eton Pharmaceuticals stock?
The average analyst price target for Eton Pharmaceuticals is $54.75. The current price is $45.00, which gives an upside of 21.7%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $49.28 and $60.23.
Is Eton Pharmaceuticals a dividend stock?
No, Eton Pharmaceuticals does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Eton Pharmaceuticals stock?
Eton Pharmaceuticals is rated as a stock with high risk. the annual standard deviation is 55.8%, which classifies the stock as high risk.
Is Eton Pharmaceuticals overvalued?
No, Eton Pharmaceuticals is considered undervalued based on the analyst price target (21.7% upside). Eton Pharmaceuticals has the following valuation ratios: a P/S ratio of 14.4, a P/B ratio of 41.5. The analyst price target suggests that the stock is undervalued by 21.7%.
Is Eton Pharmaceuticals overbought?
No, Eton Pharmaceuticals is not overbought. RSI is at 63.6 (neutral zone). The technical indicators show: RSI is at 63.6 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 5.8% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Eton Pharmaceuticals earnings report?
Eton Pharmaceuticals reports its next earnings on August 13, 2026. The stock currently trades at $45.00.
Is Eton Pharmaceuticals shorted?
Yes, Eton Pharmaceuticals is shorted with 6.3% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. Data is updated daily based on official filings with the SEC.
Are insiders buying Eton Pharmaceuticals stock?
No, insiders are not buying Eton Pharmaceuticals shares – they are net sellers. Over the last 3 months, insiders have made 1 purchases and 9 sales. On a net basis, 11,656,970 $ worth of shares were sold. Across the last 20 reported transactions, the split is 3 purchases and 17 sales, with a net 11,900,273 $ sold. Active sellers include Opaleye Management Inc., Adams Jennifer McKie, BRYNJELSEN SEAN and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Eton Pharmaceuticals a good stock?
Based on our total score, Eton Pharmaceuticals is rated as a mediocre stock with a total score of 52 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 5/100, Quality: 53/100, Momentum: 99/100. In addition: analysts see 21.7% upside to the price target; technical signal: Strong Buy. Whether Eton Pharmaceuticals is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Eton Pharmaceuticals stock?
The outlook for Eton Pharmaceuticals based on current data: the average analyst price target is $54.75 (+21.7%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 8/13/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Eton Pharmaceuticals stock rising?
Eton Pharmaceuticals is rising right now. The technical indicators show: the price is 5.8% above the 20-day average; MACD is positive with rising momentum (bullish signal); short interest is 6.3% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Eton Pharmaceuticals go?
The average analyst price target for Eton Pharmaceuticals is $54.75, which corresponds to a potential gain of 21.7% from the current price of $45.00. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Eton Pharmaceuticals fall?
We lack enough history to give a specific floor for Eton Pharmaceuticals. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Eton Pharmaceuticals do?
Eton Pharmaceuticals driver en specialforretning inden for medicin og fokuserer på at udvikle og sælge lægemidler til sjældne sygdomme. De tjener penge ved at kommercialisere produkter, som patienter med meget specifikke lidelser har brug for.
Eton er især kendt for ALKINDI S... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - Specialty & Generic industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Eton Pharmaceuticals as an investment.
Did Eton Pharmaceuticals raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Eton Pharmaceuticals. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Eton Pharmaceuticals making money or losing money?
No, Eton Pharmaceuticals is currently not making money — the company is losing money with a negative profit margin of -1.7%, a small loss. That means the business loses money on every dollar of revenue. The operating margin, however, is positive at 11.4% — the core business makes money; the loss comes from financing costs, taxes or one-off items. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Eton Pharmaceuticals go bankrupt?
The bankruptcy risk of Eton Pharmaceuticals is rated as elevated. Altman Z2 (a model for assessing financial distress) is -2.52 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 212% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Eton Pharmaceuticals have a lot of debt?
Yes, Eton Pharmaceuticals has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 212%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Eton Pharmaceuticals service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is 0.9x, and the company has more cash than debt (net cash).
